LBRX LB Pharmaceuticals Inc - Common Stock
$27.83
Price · May 20, 2026
Fundamentals as of May 12, 2026
52W Range
$13–$33
72% of range
Analyst Rating
BUY
12 analysts
Price Target
$44
+58% upside
P/E (TTM)
-7.1
ROE
-25.5%
Net Profit Margin
—
LBRX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$27.83
Market Cap
$563M
P/E (TTM)
-7.1
EPS (TTM)
$-3.13
Revenue (TTM)
—
Div Yield
—
ROE
-25.5%
Debt/Equity
—
52W Range
$13 – $33
LBRX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
$-3.13
2024-12-31
→
2025-12-31
Free Cash Flow
$-35M
2025-12-31
→
2025-12-31
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
LBRX
Peer Median
P/E (TTM)
-7.1
116.0
P/B
1.9
4.0
Price / FCF
-16.0
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
LBRX
Peer Median
ROA
-14.5%
-3.0%
ROE
-25.5%
-18.9%
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
LBRX
Peer Median
Current Ratio
41.4
2.5
Quick Ratio
39.7
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
LBRX
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
LBRX
Peer Median
LBRX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
12 analysts
- Strong Buy 4 33.3%
- Buy 7 58.3%
- Hold 1 8.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
6 analysts · 2026-05-15
Median
$38.00
Mean
$44.00
← Below all targets
$27.83
Low
$31.00
High
$78.00
Median target
$38.00
+36.5%
Mean target
$44.00
+58.1%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.02%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.67 | $-0.76 | 0.09% |
| Dec. 31, 2025 | $-0.45 | $-0.46 | 0.01% |
| Sept. 30, 2025 | $-0.61 | $-0.46 | -0.15% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| LBRX | $563M | -7.1 | — | — | -25.5% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | — |
| ESPR | — | -33.6 | 21.3% | -5.6% | 6.2% | — |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| RLMD | $354M | -3.3 | 93.7% | — | -112.0% | — |
| SGP | — | — | — | — | 50.0% | — |
| BIOA | $495M | -5.9 | — | -896.1% | -28.4% | — |
| ANRO | $568M | -8.1 | — | — | -46.1% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 13
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| R&D Expense | $17M | $51M | |
| SG&A Expense | $14M | $14M | |
| Operating Expenses | $30M | $65M | |
| Interest Income | $4M | $2M | |
| Other Non-op | $5M | $2M | |
| Pretax Income | $-25M | $-63M | |
| Income Tax | $1.0K | $1.0K | |
| Net Income | $-25M | $-63M | |
| EPS (Basic) | $-3.13 | $-176.15 | |
| EPS (Diluted) | $-3.13 | $-176.15 | |
| Shares (Basic) | 8,045,145 | 358,229 | |
| Shares (Diluted) | 8,045,145 | 358,229 | |
| EBITDA | $321.0K | · |
Balance Sheet 19
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $250M | $23M | |
| Short-term Investments | $45M | $5M | |
| Prepaid Expense | $13M | $880.0K | |
| Current Assets | $308M | $29M | |
| PP&E (Net) | $2M | $2M | |
| PP&E (Gross) | $2M | $2M | |
| Accum. Depreciation | $420.0K | $101.0K | |
| Total Assets | $313M | $34M | |
| Accounts Payable | $2M | $2M | |
| Accrued Liabilities | $5M | $5M | |
| Current Liabilities | $7M | $8M | |
| Capital Leases | $3M | $3M | |
| Total Liabilities | $12M | $14M | |
| Common Stock | $3.0K | $1.0K | |
| Retained Earnings | $-130M | $-104M | |
| AOCI | $168.0K | $111.0K | |
| Stockholders' Equity | $301M | $-95M | |
| Liabilities + Equity | $313M | $34M | |
| Shares Outstanding | 25,299,372 | 251,655 |
Cash Flow 10
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| D&A | $321.0K | $91.0K | |
| Stock-based Comp | $4M | $3M | |
| Deferred Tax | $0 | $0 | |
| Other Non-cash | $-15M | · | |
| Operating Cash Flow | $-35M | $-53M | |
| CapEx | $52.0K | $769.0K | |
| Investing Cash Flow | $-40M | $23M | |
| Financing Cash Flow | $303M | $38M | |
| Net Change in Cash | $227M | $8M | |
| Free Cash Flow | $-35M | · |
Profitability 2
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| ROA | -14.5% | · | |
| ROE | -25.5% | · |
Liquidity & Solvency 2
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 41.4 | · | |
| Quick Ratio | 39.7 | · |
Valuation (TTM) 8
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Net Income TTM | $-25M | · | |
| Market Cap | $563M | · | |
| P/E | -7.1 | · | |
| P/B | 1.9 | · | |
| P / Tangible Book | 1.9 | · | |
| P / Cash Flow | -16.0 | · | |
| P / FCF | -16.0 | · | |
| Earnings Yield | -14.1% | · |
Income Statement 12
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| R&D Expense | $15M | $8M | $2M | $3M | $376.0K | |
| SG&A Expense | $7M | $5M | $3M | $3M | $5M | |
| Operating Expenses | $22M | $14M | $5M | $6M | $6M | |
| Interest Income | $3M | $3M | $707.0K | $236.0K | $298.0K | |
| Other Non-op | $3M | $2M | $2M | $1M | $469.0K | |
| Pretax Income | $-19M | $-11M | $-4M | $-5M | $-5M | |
| Income Tax | $0 | $1.0K | $0 | $0 | $1.0K | |
| Net Income | $-19M | $-11M | $-4M | $-5M | $-5M | |
| EPS (Basic) | $-0.67 | $3.13 | $-0.61 | $-14.79 | $-14.00 | |
| EPS (Diluted) | $-0.67 | $3.13 | $-0.61 | $-14.79 | $-14.00 | |
| Shares (Basic) | 28,241,701 | 5,849,946 | 5,806,862 | 358,777 | 338 | |
| Shares (Diluted) | 28,241,701 | 5,849,946 | 5,806,862 | 358,777 | 338 |
Balance Sheet 19
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $321M | $250M | $270M | · | $23M | |
| Short-term Investments | $45M | $45M | $45M | · | $5M | |
| Prepaid Expense | $23M | $13M | $2M | · | $880.0K | |
| Current Assets | $389M | $308M | $316M | · | $29M | |
| PP&E (Net) | $2M | $2M | $2M | · | $2M | |
| PP&E (Gross) | $2M | $2M | $2M | · | $2M | |
| Accum. Depreciation | $502.0K | $420.0K | $337.0K | · | $101.0K | |
| Total Assets | $393M | $313M | $321M | · | $34M | |
| Accounts Payable | $7M | $2M | $3M | · | $2M | |
| Accrued Liabilities | $3M | $5M | $3M | · | $5M | |
| Current Liabilities | $11M | $7M | $7M | · | $8M | |
| Capital Leases | $3M | $3M | $3M | · | $3M | |
| Total Liabilities | $15M | $12M | $11M | · | $14M | |
| Common Stock | $3.0K | $3.0K | $3.0K | · | $1.0K | |
| Retained Earnings | $-149M | $-130M | $-118M | · | $-104M | |
| AOCI | $208.0K | $168.0K | $-53.0K | · | $111.0K | |
| Stockholders' Equity | $379M | $301M | $310M | · | $-95M | |
| Liabilities + Equity | $393M | $313M | $321M | · | $34M | |
| Shares Outstanding | 28,674,827 | 25,299,372 | 25,299,102 | · | 251,655 |
Cash Flow 7
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $2M | · | $634.0K | $2M | |
| Operating Cash Flow | $-23M | $-18M | · | $-8M | $-6M | |
| CapEx | $32.0K | $40.0K | · | $21.0K | $238.0K | |
| Investing Cash Flow | $-32.0K | $-40.0K | · | $5M | $14M | |
| Financing Cash Flow | $94M | $-1M | · | $0 | $0 | |
| Net Change in Cash | $71M | $-19M | · | $-3M | $8M | |
| Free Cash Flow | $-23M | · | · | · | · |
Profitability 2
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| ROA | -9.7% | · | -2.2% | · | · | |
| ROE | -10.1% | · | -2.3% | · | · |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Current Ratio | 35.7 | · | 47.6 | · | · | |
| Quick Ratio | 33.5 | · | 47.3 | · | · |
Valuation (TTM) 6
| Metric | Trend | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Net Income TTM | $-33M | · | $-28M | · | · | |
| Market Cap | $707M | · | $399M | · | · | |
| P/B | 1.9 | · | 1.3 | · | · | |
| P / Tangible Book | 1.9 | · | 1.3 | · | · | |
| P / Cash Flow | -30.4 | · | · | · | · | |
| P / FCF | -30.3 | · | · | · | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Net Income | $-25M | $-63M |
| Diluted EPS | $-3.13 | $-176.15 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Current Ratio | 41.4 | — |
| Quick Ratio | 39.7 | — |
Cash Flow
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Free Cash Flow | $-35M | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.